Qilian International Holding Group

General Information

Through our wholly owned indirect subsidiaries and the contractual arrangements described below, we are a pharmaceutical and chemical company based in China that focuses on the development, manufacture, marketing, and sale of oxytetracycline products, licorice products, traditional Chinese medicine derivatives (“TCMD”) product, heparin product, sausage casings, and fertilizers. We independently developed all of our products within our research and development department. Our products are sold in more than 20 provinces in China.

 (Note: Qilian priced its IPO at $5, the low end of its $5-to-$7 range, on Jan. 11, 2021, on 5 million shares, the same number of shares in the prospectus, to raise $25.0 million.)
Employees: 279
Founded: 2019
Contact Information
Address Jiuquan Economic and Technological Development Zone, Jiuquan City, Gansu Province, 735000 People’s Republic of China
Phone Number +86-0937-2689523
Web Address
View Prospectus: Qilian International Holding Group
Financial Information
Market Cap $175mil
Revenues $46.7 mil (last 12 months)
Net Income $3.8 mil (last 12 months)
IPO Profile
Symbol QLI
Exchange NASDAQ
Shares (millions): 5.0
Price range $5.00 - $5.00
Est. $ Volume $25.0 mil
Manager / Joint Managers Univest Securities
CO-Managers Loop Capital Markets/ Alexander Capital
Expected To Trade: 1/12/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change